The crystal structure of recombinant human inter; leukin-4 (rhuIL-4) was initially determined at 3.5-A resolution by multiple isomorphous replacement techniques and subsequently refined to a resolution of Interleukin 4 (IL-4), ' originally described in the mouse system as a B-cell growth factor (l), is a highly pleiotropic lymphokine exhibiting both stimulatory and inhibitory effects on the growth, differentiation, and functional activity of Band T-lymphocytes, myeloid cells, and cells of nonhemopoietic origin (reviewed in Refs. 2-5). In particular, recombinant human IL-4 (rhuIL-4) co-stimulates the proliferation of activated B-and T-cells (6-8), enhances the production of specific immunoglobulin subclasses, most notably IgE (9), augments the cytotoxic activity of lymphocytes and monocytes (10-12), and enhances the functional activity of myeloid cells (13, 14) . Effects of rhuIL-4 on nonhemopoietic cells include enhancement of fibroblast chemotaxis (15) The mature protein sequence of rhuIL-4 contains 129 amino acids, including two potential sites for N-linked glycosylation. The amino acid sequences as deduced from the cDNAs have been reported for human (7), murine (25, 26), and rat IL-4 (27). The human and murine proteins share a sequence identity of 41%. RhuIL-4 contains 6 cysteine residues, which form three disulfide bonds, linking the 1st and 6th, 2nd and 4th, and 3rd and 5th cysteines, respectively (28). The disulfide bonding pattern in muIL-4 is similar to that of rhuIL-4, except that in the former the disulfide bond between the 1st and 6th Cys residues has been replaced by a bond between the 1st and 5th Cys residues. These differences may be part of the reason for the strict species specificity of human and murine IL-4.
The crystal structure of recombinant human inter; leukin-4 (rhuIL-4) was initially determined at 3. Interleukin 4 (IL-4), ' originally described in the mouse system as a B-cell growth factor (l), is a highly pleiotropic lymphokine exhibiting both stimulatory and inhibitory effects on the growth, differentiation, and functional activity of Band T-lymphocytes, myeloid cells, and cells of nonhemopoietic origin (reviewed in Refs. 2-5). In particular, recombinant human IL-4 (rhuIL-4) co-stimulates the proliferation of activated B-and T-cells (6) (7) (8) , enhances the production of specific immunoglobulin subclasses, most notably IgE (9) , augments the cytotoxic activity of lymphocytes and monocytes (10) (11) (12) , and enhances the functional activity of myeloid cells (13, 14) . Effects of rhuIL-4 on nonhemopoietic cells include enhancement of fibroblast chemotaxis (15) and the adhesiveness of endothelial cells for T cells (16) . The multiple biological activities of rhuIL-4 are apparently mediated through binding to specific high-affinity cell surface receptors, which display a wide distribution on various cell types (17- * This research was supported by Grant CA-13148 from the National Institutes of Health and Grant NAGW813 from the National Aeronautics and Space Administration. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
aca, NY 14853. II Present address: Dept. of Biochemistry, Cornel1 University, Ith-' The abbreviations used are: IL-4, interleukin 4; rhuIL-4, recombinant human interleukin 4; muIL-4, murine IL-4; GM-CSF, granulocyte-macrophage colony-stimulating factor; rhuGM-CSF, recombinant human granulocyte-macrophage colony-stimulating factor; MIR, multiple isomorphous replacement. 19 ). Inhibitory effects of rhuIL-4 on the in vitro growth of chronic lymphocytic B-cells (20) and various lymphoid neoplasms (21) as well as potent anti-tumor activity demonstrated by murine IL-4 (muIL-4) in various in uiuo models (22) (23) (24) have supported an application for rhuIL-4 in cancer therapy, which is currently being evaluated in Phase 1/11 clinical trials.
The mature protein sequence of rhuIL-4 contains 129 amino acids, including two potential sites for N-linked glycosylation. The amino acid sequences as deduced from the cDNAs have been reported for human (7) , murine (25, 26) , and rat IL-4 (27) . The human and murine proteins share a sequence identity of 41%. RhuIL-4 contains 6 cysteine residues, which form three disulfide bonds, linking the 1st and 6th, 2nd and 4th, and 3rd and 5th cysteines, respectively (28) . The disulfide bonding pattern in muIL-4 is similar to that of rhuIL-4, except that in the former the disulfide bond between the 1st and 6th Cys residues has been replaced by a bond between the 1st and 5th Cys residues. These differences may be part of the reason for the strict species specificity of human and murine IL-4.
RhuIL-4 contains a high a-helical content (-73%) as deduced from circular dichroism studies (29) . A model of IL-4 has been proposed, based on the CD studies, human-mouse chimeras, and secondary structure predictions, that includes a right-handed antiparallel four-helix bundle (30) . However, a preliminary NMR structure of rhuIL-4 confirmed the presence of a left-handed antiparallel four-helix bundle and a smaller two-strand /?-sheet. Similar left-handed four-helix bundle topology has previously been observed in growth hormone (31), interferon+' (32), and GM-CSF (33, 34) . Here we report the x-ray crystal structure of rhuIL-4 at 2.35 A resolution.
EXPERIMENTAL PROCEDURES
RhuIL-4 was expressed periplasmically in Escherichia coli (35) and purified as described previously (36) . Crystals for x-ray diffraction studies were grown by the conditions described by Cook et al. (37) . The space group is P41212 with cell parameters a = b = 91.8 and c = 46.2 A. There is one molecule in the asymmetric unit, and the solvent volume fraction is about 60%.
Potential heavy-atom derivatives were prepared by soaking crystals of rhuIL-4 for 24 h at 22 "C in 65% saturated ammonium sulfate solutions that contained 50 mM cacodylate buffer, pH 5.8. Screening for heavy-atom derivatives was carried out using a Nicolet X-100A area detector and CuKa radiation from a Rigaku rotating anode generator operating at 100 mA and 40 kV. Data frames covered 0.25" and were measured for 5 min. Indexing and integration of intensity data were carried out using the XENGEN processing programs (38) . Potential heavy-atom derivatives were scaled to the native data using relative Wilson plots. Analysis of the data using an automated difference Patterson search, written by the authors, identified two heavyatom derivatives, KAuC14 and K2PtC1,. One heavy-atom site was identified in the difference Patterson searches for KAuCh and K2PtCL, derivatives. In each case, the site was the largest peak at 5.7 (KAuC14) and 5.5 (K2PtCL,) times the root mean square background of the search map. The heavy-atom parameters were refined against the centric data. Summaries of the data collection and refinement statistics are shown in Table I . Heavy-atom refinement, MIR phase calculations, and phase combination were done with the CCP4 package of programs (CCP4 Program Suite, Daresbury Laboratories, Great Britain).
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MIR phases were calculated based on the Au and Pt derivatives. The overall figure of merit for data to 3.5 8, was 0.56 for 2664 reflections. Inspection of tke MIR electron density map calculated with data from 15-to 3.5-A resolution revealed several large main chain breaks and poor side chain definition. The MIR phases were improved by solvent leveling using the ISIR/ISAS programs of Wang (39) . After convergence, the overall figure of merit was 0.79, the average accumulated phase shift was 32.7', and the correlation coefficient between F. and F, was 0.952. Inspection of the solvent-leveled map revealed four a-helices with well defined main chain density and generally well defined side chain density. A portion of the 15-3.5-A MIR/solvent-leveled electron density map is shown in Fig. 1 .
Four idealized polyalanine a-helices containing a total of 53 residues were fit to the 3.5-A MIR/solvent-leveled electron density map. The helices were refined as four rigid bodies with data between 6 and 3.5 A using the program X-PLOR (40) . Phases were calculated for this model and combined with the MIR phases between 6 and 3.5 A.
The original MIR phases were used for data between 15 and 6 A. The combined phase set was solvent-leveled and used to calculate a new 15-3.5-A electron density map. Analysis of this map showed greatly enhanced side chain definition in the helices and probable main chain density for two previously unobserved loops. Based on the four-helix bundle observed in the electron density map of rhuIL-4, the coordinates of recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF), whose structure was previously determined in our lab (34) , were fit into the rhuIL-4 3.5-A electron density map.
The general structural correspondence of rhuGM-CSF with the electron density found in the rhuIL-4 map suggested the probable identity of helices A, B, C, and D. Confirmation of the identity of the helices was obtained by aligning and building a complete atomic model for the four helices consisting of residues 6-18, 40-59, 70-92, and 112-127. The rhuGM-CSF model was not used for any further electron density interpretation. The positions of the main chain atoms for the loops connecting the helices were located from the map An overall isotropic temperature factor of 15.0 A' was used in steps 1-4. In step 3, the model was refit to 15-2.8-A resolution electron density maps using combined phases. In these maps, MIR phases were used for 15-6-A data, a combination of the MIR and calculated phases were used for 6-3.5-A data, and calculated phases were used for 3.5-2.8-A data. Refitting at 2.5 and 2.35 8, was done using 2F0 -F, maps with calculated phases. R-factor calculations are for all data within the specified resolution limits. R-factor is defined as (ZIFobs -Fcaic1)/ ZF,b, where Fobs represents the observed structure-factor amplitudes from the native data and Fcele the structure-factor amplitudes calculated from the model. for each helix were calculated as described in Presnell and Cohen
RESULTS AND DISCUSSION
Interhelix packing angles and the percentage of buried surface area calculated with combined phases at 3.5 A, although the side chain definition for residues in the loops was generally poor. Thus, a second round of rigid body refinement using the full atom four-helix model (residues 6-18,40-59,70-92, and 112-127) was done at 3.5 A, followed by phase combination and solvent-leveling as described above. This series of map modification steps further improved the quality of the side chain density for the loops of rhuIL-4. This 15-3.5-A electron density map was used to build a full atom model of rhuIL-4 consisting of all 129 amino acids. The initial model with 129 amino acids had an R-factor of 0.446
for all data between 6 and 3.5 A. The model was refined in six steps by simulated annealing with the program X-PLOR and then with restrained least-squares using the program PROLSQ (41) to an Rfactor of 0.232 for all data between 6 and 2.35 A. Table I1 (Figs. 2 and 3) . It is interesting to note that helix D has been proposed as the preliminary recognition helix for several cytokines (44) and has been shown to interact with the receptor in the human growth hormone-receptor complex (42, 45) .
The four helices of the bundle donate 18 hydrophobic residues to the interior of the bundle to form a closely packed hydrophobic core (Table 111 ). The helices are connected by one short and two long segments to form a left-handed bundle topology (43) . These connecting segments include residues 19-40 (AB loop), 59-69 (BC loop), and 95-108 (CD loop).
Residues 27-31 and 105-108 within the two long connections form a two-stranded antiparallel @-sheet. The carbonyl oxygen of Leuz7 forms a hydrogen bond to the main chain nitrogen of Ledm, which is the first residue in helix D.
RhuIL-4 contains three disulfide bonds and no free cysteine residues. Cys3 and CyslZ7 form a disulfide bond that links the N and C termini of the molecule. CysZ4 is located near the Cterminal end of helix A and forms a disulfide bond with Cyss5, which is in the BC loop. Cys4'j is in the middle of helix B and forms a disulfide bond with Cysg9 located in the CD loop. The three disulfide bonds link the polypeptide chain at the three most spatially distant parts of the molecule. This arrangement of disulfide bonds connects all of the potentially flexible regions of the molecule and probably contributes to the high thermal stability of rhuIL-4 (29) .
RhuIL-4 contains two potential sites for N-linked glycosylation at positions 38-40 and 105-107. The first is located at the N-terminal end of helix B, whereas the second is located near the N-terminal end of helix D (Fig. 2) . Both sites are on the surface of the molecule and exposed to the solvent. The first glycosylation site consisting of residues 38-40 is the only site used by C127 mammary tumor cells (46) . MuIL-4 contains three potential sites for N-linked glycosylation at Am", Asn", and A m g 7 (numbering according to the mature murine sequence (Fig. 4) . The positions of the first and third of these sites correspond closely in position to the human N-linked sites. Amino acid sequencing of purified recombinant muIL-4 suggests that the first N-linked site is occupied, whereas the third site is most probably nonglycosylated (47) . Assuming that the tertiary structure of muIL-4 is similar to rhuIL-4, the third potential murine glycosylation site would be located near the N-terminal end of helix C, which is also located in a solvent accessible area. The sulfur atoms in the disulfide bonds are represented as yellow spheres. One of the potential glycosylation sites for huIL-4 (residues 38-40) is coloredgreen. The glycosylation site that is unique to muIL-4 (residues 76-78 based on human numbering) is colored purple. The figure was prepared using the programs described by Carson (51). This is the second example of a cytokine which displays both a four a-helix bundle and &sheet secondary structure. Based on current secondary structure assignments, rhuIL-4 consists of 58% helix and 7% 0 structure. The helices are connected to form a left-handed four-helix bundle consisting of one short loop and two long overhand polypeptide segments. Our model is consistent with far ultraviolet circular dichroic spectra which predicted a high helical content (-73%) and the location of Trpgl on the surface of the protein (29) . The exon boundaries for rhuIL-4 suggest that loop regions should be at or near residues 21, 37, and 96, which is supported by our structure.
There are significant differences between our model of rhuIL-4 and a predicted model of IL-4 (30) . In addition to differences in the beginning and end points of the helices, the largest error in the predicted model was the assumption that the four-helix bundle was right-handed. However, the secondary structure assignments of our model of rhuIL-4 agree well with the secondary structure assignments based on threedimensional nuclear magnetic resonance experiments, which were carried out at approximately the same pH as our crystal structure analysis (48). The largest differences were in the assignment of the starting and ending residues for the ahelices and &strands. In contrast to the preliminary NMR structure, we have been able to define the helix packing angles and the structure of the loops. A detailed comparison of the crystal and solution structures of rhuIL-4 will have to await a more complete NMR structure determination. However, it seems likely that any differences in the x-ray and NMR structures will be small, considering the constraints of the three disulfide bridges on the tertiary structure of the protein.
MuIL-4 exhibits approximately 41% sequence identity with huIL-4 (Fig. 4) . Based on the amino acid sequence identity, it is expected that muIL-4 and rhuIL-4 have similar tertiary structures. Although there are three disulfide bonds in each molecule, only 5 of the 6 cysteine residues can be aligned between the primary sequences of murine and rhuIL-4. C~S '~' in rhuIL-4 is not present in the muIL-4 sequence but has been replaced with Cyss7 which corresponds to residue 92 in rhuIL-4. Thus the disulfide composed of Cys3 and C~S '~' in rhuIL-4 is not found in muIL-4. Instead, there is a disulfide linkage between Cys' and Cyssl (corresponding to Cys3 and Glyg2 in rhuIL-41, whereas the other two disulfides are located in similar positions relative to rhuIL-4. The result of this change is to link the N terminus of the molecule to the Cterminal end of helix C rather than the C-terminal end of helix D. The distance between Cys3 and Glyg2 is approximately 13 A, and the residues are not oriented properly to form a disulfide bond even if both residues were cysteines. Residue-6 is closest to residue 92 at a distance of approximately 8 A.
However, rotation of the 4,J/ angles for residues 1-6 would bring Cys3 into a position with reasonable geometry and the proper distance to form the new disulfide bond. The overall effect of this disulfide bond in muIL-4 relative to rhuIL-4 is to move the N terminus of the protein toward the C-terminal end of helix C and away from helix D. In addition to differences in the disulfide bonds, muIL-4 is composed of 120 residues instead of 129. Sequence alignment suggests that 7 residues are deleted from the BC loop and helix C, and four are deleted from the C terminus, whereas 2 residues are added at the N terminus. Thus, the major differences between the human and murine structures occur in the BC loop and adjacent helical residues on one end of the molecule and in residues at the C-terminal end of helix C around the new disulfide bond on the other end of the molecule. RhuIL-4 is the fourth four-helix bundle cytokine to display up-up-down-down topology. With the exception of IL-2, which also contains a left-handed four-helix bundle but no overhand connections, the left-handed four-helix bundle with two overhand connections is the only topology that has been observed for the ligands of the class 1 hematopoietic receptors as described by Bazan (44). Other cytokines and growth factors which display this topology as determined by x-ray crystal structures include porcine (31) and human growth hormone (42) , interferon-@ (32), and GM-CSF (33, 34) . Interferon-y is a dimeric molecule which is more distantly related to the monomeric cytokines (49). In fact, to our knowledge, this topology has only been observed for these five proteins. For the monomeric cytokines and growth hormone, there are differences in the length of the helices, the helix packing angles, and the positioning and secondary structures of the loops which connect the helices. From this small sample of cytokine crystal structures, it appears that this topology may have evolved for regulation of the immune and/or the hematopoietic systems. Several theoretical and experimental studies have also suggested that other hormones and cytokines in this family (prolactin, erythropoietin, granulocyte colonystimulating factor, and interleukins 3, 6, and 7) will have similar topology to the five that have been determined by xray crystallography.
Of the five cytokine and growth factor crystal structures known in this family of proteins, the greatest structural similarity is observed between rhuIL-4 and rhuGM-CSF. This may be due partially to the similar size of the polypeptide chains. Sixty-three Ca atoms in rhuIL-4 and rhuGM-CSF can he superimposed to give a root mean square deviation of 1.4 A (Fig. 5) . Most of these residues, which compose approximately 49% of the structures, are found in the four-helix bundles and two @-strands. The largest structural differences between the two molecules occur in the BC loop region, which is 29 residues longer in rhuIL-4 relative to rhuGM-CSF. These additional residues are accounted for by an increase in the length of the C-terminal end of helix B and the N-terminal end of helix C by 6 and 12 residues, respectively. Conse; quently, the BC loop in rhuIL-4 extends approximately 17 A beyond the BC loop of rhuGM-CSF. It is interesting that amino acid sequence alignment of rhuIL-4 with rat or mouse IL-4 shows a seven residue deletion corresponding to the Nterminal end of helix C. Other large differences in the structures occur at the opposite end of the bundle axis, which includes the C-terminal end of helix C as well as the N and C termini of the molecule.
There is a paucity of published data on the structureactivity relationship in rhuIL-4. Reduction of the three disulfide bonds followed by alkylation resulted in a complete loss in biological activity (28, 29) . Chemical modification of Trpgl and TyrlZ4 caused only partial losses in activity, indicating that neither residue is absolutely required for full biological activity. It has also been observed employing synthetic polypeptides that residues 46-64 and 65-98 induce fibroblast chemotaxis, similar to the effects of rhuIL-4 (15). An interpretation of the significance of these data requires a more detailed elucidation of structure-activity relationship.
Although relatively little is known about which residues in IL-4 are responsible for receptor binding and/or bioactivity, a large amount of work has been done on the growth hormone and GM-CSF systems. Although there are significant differences between the structures of growth hormone and GM-CSF, the overall topology and the areas of interaction with their receptors appear to be very similar (34, 42) . Based on the x-ray crystal structure of a complex of human growth hormone with its receptor (42) and the structural similarity of rhuIL-4 with human growth hormone and rhuGM-CSF, a model of potential residues involved in receptor binding to IL-4 can be constructed. Using this method, residues that are likely to be involved in receptor binding include the surface residues which make up helix A, loop AB, the C-terminal end of helix C , and helix D. This model will need to be evaluated biochemically and ultimately by a crystal structure of the IL-4/receptor complex.
